43:@0.895357:0.033217:0.916054:0.033217:0.916054:0.013052:0.895357:0.013052:0.010348:0.010348
HANDBOOK OF GENERAL MEDICINE VOL 1:@0.649278:0.972666:0.923020:0.972666:0.923020:0.958637:0.649278:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
TREATMENT AppROACHEs:@0.983817:0.243404:0.983817:0.056389:0.958557:0.056389:0.958557:0.243404:0.008796:-0.015759:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.114251:0.006043:0.014598:-0.134892:0.158619:-0.158619:0.000000:0.000000:0.000000:0.000000:0.242661:0.009202
TREATMENT AppROACHEs:@0.397039:0.033156:0.624383:0.033156:0.624383:0.013866:0.397039:0.013866:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
A recent review states that ACEIs reduce the risk of :@0.090476:0.084931:0.485159:0.084931:0.485159:0.069149:0.090476:0.069149:0.011188:0.006290:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.006290:0.004551:0.009827:0.008376:0.003024:0.009827:0.012564:0.006290:0.005866:0.005125:0.010326:0.005125:0.009827:0.005866:0.006290:0.005125:0.009223:0.010326:0.005125:0.006290:0.011188:0.012292:0.008104:0.003417:0.005866:0.006290:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.006290:0.005125:0.009223:0.009827:0.006290:0.004551:0.003024:0.005866:0.007590:0.006290:0.009903:0.004747:0.004188
progression to macro-albuminuria in normotensive pa-:@0.076189:0.099167:0.480940:0.099167:0.480940:0.083384:0.076189:0.083384:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.005881:0.005125:0.009903:0.005896:0.014182:0.010326:0.009782:0.004551:0.009903:0.005020:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.005896:0.003024:0.009223:0.005896:0.009223:0.009903:0.004551:0.014182:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.005881:0.010311:0.010326:0.005020
tients with micro-albuminuria and type 1 diabetes mel-:@0.076189:0.113402:0.480971:0.113402:0.480971:0.097620:0.076189:0.097620:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005065:0.012564:0.003024:0.005125:0.009223:0.005065:0.014182:0.003024:0.009782:0.004551:0.009903:0.005020:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.005065:0.010326:0.009223:0.010357:0.005065:0.005125:0.008104:0.010311:0.009827:0.005065:0.008376:0.005065:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.005065:0.014182:0.009827:0.003024:0.005020
litus. ACEIs and ARBs reduce the risk of progression to :@0.076189:0.127638:0.485128:0.127638:0.485128:0.111855:0.076189:0.111855:0.003024:0.003024:0.005125:0.009192:0.005866:0.004188:0.006335:0.011188:0.012292:0.008104:0.003417:0.005866:0.006350:0.010326:0.009223:0.010357:0.006335:0.011188:0.009177:0.008678:0.005866:0.006335:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.006335:0.005125:0.009223:0.009827:0.006335:0.004551:0.003024:0.005866:0.007590:0.006335:0.009903:0.004747:0.006335:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.006335:0.005125:0.009903:0.004188
macro-albuminuria in normotensive patients with micro-:@0.076189:0.141873:0.480956:0.141873:0.480956:0.126091:0.076189:0.126091:0.014182:0.010326:0.009782:0.004551:0.009903:0.005020:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.003629:0.003024:0.009223:0.003629:0.009223:0.009903:0.004551:0.014182:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.003613:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003629:0.012564:0.003024:0.005125:0.009223:0.003629:0.014182:0.003024:0.009782:0.004551:0.009903:0.005020
albuminuria and TIIDM. ACEIs and ARBs, however,  do :@0.076189:0.156109:0.485144:0.156109:0.485144:0.140326:0.076189:0.140326:0.010326:0.003024:0.010311:0.009192:0.014182:0.003024:0.009223:0.009192:0.004551:0.003024:0.010326:0.006758:0.010326:0.009223:0.010357:0.006758:0.006441:0.003417:0.003417:0.011249:0.013894:0.004188:0.006758:0.011188:0.012292:0.008104:0.003417:0.005866:0.006758:0.010326:0.009223:0.010357:0.006758:0.011188:0.009177:0.008678:0.005866:0.004188:0.006758:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004188:0.002555:0.010357:0.009903:0.004188
not  consistently reduce  the  serum  creatinine  levels.  :@0.076189:0.170344:0.485140:0.170346:0.485140:0.154563:0.076189:0.154562:0.009223:0.009903:0.005125:0.004188:0.003689:0.009782:0.009903:0.009223:0.005866:0.003024:0.005866:0.005125:0.009827:0.009223:0.005125:0.003024:0.008104:0.007892:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004188:0.003689:0.005125:0.009223:0.009827:0.004188:0.003689:0.005866:0.009827:0.004551:0.009192:0.014182:0.004188:0.003689:0.009782:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.003024:0.009223:0.009827:0.004188:0.003689:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.004188:0.009748:0.626168
15:@0.471233:0.165047:0.480949:0.165047:0.480949:0.155893:0.471233:0.155893:0.004858:0.004858
Renoprotection  is a key outcome  of RAAs  blockade :@0.076185:0.184581:0.485125:0.184581:0.485125:0.168798:0.076185:0.168798:0.009177:0.009827:0.009223:0.009903:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.003281:0.003024:0.005866:0.007484:0.010326:0.007484:0.007590:0.009827:0.008104:0.007484:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.004188:0.003281:0.009903:0.004747:0.007484:0.009177:0.011188:0.011188:0.007529:0.004188:0.003281:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.004188
with either ACEIs or ARBs.:@0.076185:0.198817:0.258868:0.198817:0.258868:0.183034:0.076185:0.183034:0.012564:0.003024:0.005125:0.009223:0.004188:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004188:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.009903:0.004551:0.004188:0.011188:0.009177:0.008678:0.005866:0.004188
A  swedish registry  analysis  of patients post MI be-:@0.090473:0.213052:0.480952:0.213052:0.480952:0.197270:0.090473:0.197270:0.011188:0.004188:0.004158:0.007529:0.012564:0.009827:0.010357:0.003024:0.005866:0.009223:0.008346:0.004551:0.009827:0.010175:0.003024:0.005866:0.005125:0.004551:0.008104:0.004188:0.004143:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.004188:0.004173:0.009903:0.004747:0.008346:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.008346:0.010311:0.009903:0.005866:0.005125:0.008346:0.013894:0.003417:0.008346:0.010311:0.009827:0.575262
tween 2006  and 2012  revealed that RAAs antagonist :@0.076185:0.227288:0.485140:0.227288:0.485140:0.211505:0.076185:0.211505:0.005125:0.012564:0.009827:0.009827:0.009223:0.006849:0.008376:0.008376:0.008376:0.008376:0.004188:0.002676:0.010326:0.009223:0.010357:0.006849:0.008376:0.008376:0.008376:0.008376:0.004188:0.002676:0.004551:0.009827:0.008376:0.009827:0.010326:0.003024:0.009827:0.010357:0.006849:0.005125:0.009223:0.010326:0.005125:0.006849:0.009177:0.011188:0.011188:0.007529:0.006849:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004188
treatment  did  not  prevent  new-onset  atrial  fibrillation, :@0.076185:0.241523:0.485125:0.241523:0.485125:0.225741:0.076185:0.225741:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004188:0.002495:0.010357:0.003024:0.010357:0.004188:0.002510:0.009223:0.009903:0.005125:0.004188:0.002510:0.010311:0.004551:0.009827:0.008376:0.009827:0.009223:0.005125:0.004188:0.002510:0.009223:0.009827:0.012564:0.005020:0.009903:0.009223:0.005866:0.009827:0.005125:0.004188:0.002510:0.010326:0.005125:0.004551:0.003024:0.010326:0.003024:0.004188:0.002510:0.003681:0.003681:0.010311:0.004551:0.003024:0.003024:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188
however, the risk of all-cause mortality in patients with :@0.076185:0.255759:0.485125:0.255759:0.485125:0.239976:0.076185:0.239976:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.005700:0.005125:0.009223:0.009827:0.005700:0.004551:0.003024:0.005866:0.007590:0.005715:0.009903:0.004747:0.005700:0.010326:0.003024:0.003024:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.005715:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.005715:0.003024:0.009223:0.005715:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005715:0.012564:0.003024:0.005125:0.009223:0.004188
or without heart failure was significantly reduced.:@0.076185:0.269994:0.434763:0.269994:0.434763:0.254212:0.076185:0.254212:0.009903:0.004551:0.004188:0.012564:0.003024:0.005125:0.009223:0.009903:0.009192:0.005125:0.004188:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.012564:0.010326:0.005866:0.004188:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.004188:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004188
16:@0.434736:0.264697:0.444452:0.264697:0.444452:0.255543:0.434736:0.255543:0.004858:0.004858
 :@0.444456:0.269995:0.448643:0.269995:0.448643:0.254213:0.444456:0.254213:0.004188
Diabetic retinopathy:  A  meta-analyses including 21 :@0.090473:0.284231:0.485126:0.284231:0.485126:0.268448:0.090473:0.268448:0.011249:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.007378:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188:0.004188:0.003175:0.011188:0.004188:0.003175:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.009827:0.005866:0.007378:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.007378:0.008376:0.008376:0.004188
randomised clinical trials with 13 823 participants repor-:@0.076186:0.298466:0.480953:0.298466:0.480953:0.282684:0.076186:0.282684:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.004430:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.004445:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004430:0.012564:0.003024:0.005125:0.009223:0.004430:0.008376:0.008376:0.004445:0.008376:0.008376:0.008376:0.004445:0.010311:0.010326:0.004551:0.005125:0.003024:0.009782:0.003024:0.010311:0.010326:0.009223:0.005125:0.005866:0.004430:0.004551:0.009827:0.010311:0.009903:0.004551:0.005020
ted that RAAs inhibitors were associated with reduced :@0.076186:0.312702:0.485141:0.312702:0.485141:0.296919:0.076186:0.296919:0.005125:0.009827:0.010357:0.005186:0.005125:0.009223:0.010326:0.005125:0.005186:0.009177:0.011188:0.011188:0.007529:0.005186:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005186:0.012564:0.009827:0.004551:0.009827:0.005186:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.009827:0.010357:0.005186:0.012564:0.003024:0.005125:0.009223:0.005186:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.439748
risk of progression (absolute risk difference −3%, 95% CI :@0.076186:0.326937:0.485126:0.326937:0.485126:0.311155:0.076186:0.311155:0.004551:0.003024:0.005866:0.007590:0.005277:0.009903:0.004747:0.005261:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.005261:0.005579:0.010326:0.010311:0.005866:0.009903:0.003024:0.009192:0.005125:0.009827:0.005277:0.004551:0.003024:0.005866:0.007590:0.005277:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005261:0.009162:0.008376:0.011717:0.004188:0.005261:0.008376:0.008376:0.011717:0.005277:0.012292:0.003417:0.004188
−5 to −1; pooled RR 0·87, 95% CI 0·80–0·95; p=0·002) and :@0.076186:0.341173:0.485111:0.341173:0.485111:0.325390:0.076186:0.325390:0.009162:0.008376:0.003462:0.005125:0.009903:0.003462:0.009162:0.008376:0.004188:0.003462:0.010311:0.009903:0.009903:0.003024:0.009827:0.010357:0.003462:0.009177:0.009177:0.003462:0.008376:0.005035:0.008376:0.008376:0.004188:0.003477:0.008376:0.008376:0.011717:0.003462:0.012292:0.003417:0.003462:0.008376:0.005035:0.008376:0.008376:0.007560:0.008376:0.005035:0.008376:0.008376:0.004188:0.003477:0.010311:0.009162:0.008376:0.005035:0.008376:0.008376:0.008376:0.005579:0.003477:0.010326:0.009223:0.010357:0.004188
increased possibility of regression of diabetic retinopa-:@0.076186:0.355409:0.480953:0.355409:0.480953:0.339626:0.076186:0.339626:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005534:0.010311:0.009903:0.005866:0.005866:0.003024:0.010311:0.003024:0.003024:0.003024:0.005125:0.008104:0.005549:0.009903:0.004747:0.005534:0.004551:0.009827:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.005518:0.009903:0.004747:0.005534:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005534:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005020
thy (8%, 1–16; RR 1·39, 95% CI 1·19–1·61; p=0·00002). A :@0.076186:0.369644:0.485156:0.369644:0.485156:0.353861:0.076186:0.353861:0.005125:0.009223:0.008104:0.005655:0.005579:0.008376:0.011717:0.004188:0.005655:0.008376:0.007560:0.008376:0.008376:0.004188:0.005655:0.009177:0.009177:0.005655:0.008376:0.005035:0.008376:0.008376:0.004188:0.005655:0.008376:0.008376:0.011717:0.005655:0.012292:0.003417:0.005655:0.008376:0.005035:0.008376:0.008376:0.007560:0.008376:0.005035:0.008376:0.008376:0.004188:0.005670:0.010311:0.009162:0.008376:0.005035:0.008376:0.008376:0.008376:0.008376:0.008376:0.005579:0.004188:0.005670:0.011188:0.004188
network  meta-analysis demonstrated  that  the  antihy-:@0.076186:0.383880:0.480953:0.383880:0.480953:0.368097:0.076186:0.368097:0.009223:0.009827:0.005125:0.012564:0.009903:0.004551:0.007590:0.004188:0.003220:0.014182:0.009827:0.005125:0.010326:0.005020:0.010326:0.009223:0.010326:0.003024:0.008104:0.005866:0.003024:0.005866:0.007423:0.010357:0.009827:0.014182:0.009903:0.009223:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.004188:0.003220:0.005125:0.009223:0.010326:0.005125:0.004188:0.003220:0.005125:0.009223:0.009827:0.004188:0.003220:0.010326:0.009223:0.005125:0.003024:0.009223:0.008104:0.005020
pertensive  medicines with  the  lowest  risk  of  diabetic :@0.076186:0.398115:0.485111:0.398115:0.485111:0.382333:0.076186:0.382333:0.010311:0.009827:0.004551:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.004188:0.003780:0.014182:0.009827:0.010357:0.003024:0.009782:0.003024:0.009223:0.009827:0.005866:0.007983:0.012564:0.003024:0.005125:0.009223:0.004188:0.003780:0.005125:0.009223:0.009827:0.004188:0.003780:0.003024:0.009903:0.012564:0.009827:0.005866:0.005125:0.004188:0.003780:0.004551:0.003024:0.005866:0.007590:0.004188:0.003780:0.009903:0.004747:0.004188:0.003780:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004188
retinopathy progression were ACEIs, followed by ARBs, :@0.076186:0.412351:0.485126:0.412351:0.485126:0.396568:0.076186:0.396568:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.005685:0.010311:0.004551:0.009903:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.005685:0.012564:0.009827:0.004551:0.009827:0.005685:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.005685:0.004747:0.009903:0.003024:0.003024:0.009903:0.012564:0.009827:0.010357:0.005685:0.010311:0.008104:0.005700:0.011188:0.009177:0.008678:0.005866:0.004188:0.004188
β-blockers,  calcium-channel  blockers,  and  placebo :@0.076186:0.426586:0.485111:0.426586:0.485111:0.410804:0.076186:0.410804:0.009011:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004188:0.006380:0.009782:0.010326:0.003024:0.009782:0.003024:0.009192:0.014182:0.005020:0.009782:0.009223:0.010326:0.009223:0.009223:0.009827:0.003024:0.004188:0.006380:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004188:0.006380:0.010326:0.009223:0.010357:0.004188:0.006380:0.010311:0.003024:0.010326:0.009782:0.009827:0.010311:0.009903:0.004188
in rank order. ACEIs were the medicines with the high-:@0.076186:0.440822:0.480953:0.440822:0.480953:0.425039:0.076186:0.425039:0.003024:0.009223:0.005534:0.004551:0.010326:0.009223:0.007590:0.005534:0.009903:0.004551:0.010357:0.009827:0.004551:0.004188:0.005518:0.011188:0.012292:0.008104:0.003417:0.005866:0.005534:0.012564:0.009827:0.004551:0.009827:0.005518:0.005125:0.009223:0.009827:0.005534:0.014182:0.009827:0.010357:0.003024:0.009782:0.003024:0.009223:0.009827:0.005866:0.005534:0.012564:0.003024:0.005125:0.009223:0.005534:0.005125:0.009223:0.009827:0.005518:0.009223:0.003024:0.010175:0.009223:0.005020
est association for regression of diabetic retinopathy. It :@0.076186:0.455057:0.485111:0.455057:0.485111:0.439275:0.076186:0.439275:0.009827:0.005866:0.005125:0.005095:0.010326:0.005866:0.005866:0.009903:0.009782:0.003024:0.010326:0.005125:0.003024:0.009903:0.009223:0.005095:0.004747:0.009903:0.004551:0.005095:0.004551:0.009827:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.009903:0.009223:0.005080:0.009903:0.004747:0.005095:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005095:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188:0.005080:0.003417:0.005125:0.004188
therefore seems as if ACE inhibitors might be better than :@0.076186:0.469293:0.485126:0.469293:0.485126:0.453510:0.076186:0.453510:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.003568:0.005866:0.009827:0.009827:0.014182:0.005866:0.003583:0.010326:0.005866:0.003598:0.003024:0.004747:0.003583:0.011188:0.012292:0.008104:0.003583:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.003583:0.014182:0.003024:0.010175:0.009223:0.005125:0.003583:0.010311:0.009827:0.003583:0.010311:0.009827:0.005125:0.005125:0.009827:0.004551:0.003583:0.005125:0.009223:0.010326:0.009223:0.004188
ARBs for treating diabetic retinopathy.:@0.076186:0.483528:0.355132:0.483528:0.355132:0.467746:0.076186:0.467746:0.011188:0.009177:0.008678:0.005866:0.004188:0.004747:0.009903:0.004551:0.004188:0.005125:0.004551:0.009827:0.010326:0.005125:0.003024:0.009223:0.010175:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004188:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188
17:@0.355110:0.478232:0.364826:0.478232:0.364826:0.469078:0.355110:0.469078:0.004858:0.004858
Despite the  sited evidence and years of  research :@0.090476:0.497766:0.485143:0.497766:0.485143:0.481984:0.090476:0.481984:0.011249:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.008497:0.005125:0.009223:0.009827:0.004188:0.004294:0.005866:0.003024:0.005125:0.009827:0.010357:0.008497:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.008497:0.010326:0.009223:0.010357:0.008497:0.008104:0.009827:0.010326:0.004551:0.005866:0.008497:0.009903:0.004747:0.004188:0.004294:0.004551:0.009827:0.005866:0.009827:0.010326:0.004551:0.009782:0.009223:0.004188
and randomised clinical trials, a recent  Cochrane  re-:@0.076189:0.512002:0.480955:0.512002:0.480955:0.496219:0.076189:0.496219:0.010326:0.009223:0.010357:0.006683:0.004551:0.010326:0.009223:0.010357:0.009903:0.014182:0.003024:0.005866:0.009827:0.010357:0.006683:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.010326:0.003024:0.006683:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.006683:0.010326:0.006683:0.004551:0.009827:0.009782:0.009827:0.009223:0.005125:0.004188:0.002480:0.012292:0.009903:0.009782:0.009223:0.004551:0.010326:0.009223:0.009827:0.004188:0.002480:0.004551:0.009827:0.005020
view  states  “All-cause  death  is  similar  for  first-line  RAS :@0.076189:0.526238:0.485143:0.526238:0.485143:0.510455:0.076189:0.510455:0.008376:0.003024:0.009827:0.012564:0.004188:0.002827:0.005866:0.005125:0.010326:0.005125:0.009827:0.005866:0.004188:0.002827:0.007590:0.011188:0.003024:0.003024:0.005020:0.009782:0.010326:0.009192:0.005866:0.009827:0.004188:0.002827:0.010357:0.009827:0.010326:0.005125:0.009223:0.004188:0.002827:0.003024:0.005866:0.004188:0.002827:0.005866:0.003024:0.014182:0.003024:0.003024:0.010326:0.004551:0.004188:0.002842:0.004747:0.009903:0.004551:0.004188:0.002827:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004188:0.002827:0.009177:0.011188:0.007529:0.004188
inhibitors and first-line CCBs, thiazides and beta block:@0.076189:0.540473:0.475951:0.540473:0.475951:0.524690:0.076189:0.524690:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005851:0.010326:0.009223:0.010357:0.005851:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005836:0.012292:0.012292:0.008678:0.005866:0.004188:0.005851:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005866:0.005851:0.010326:0.009223:0.010357:0.005851:0.010311:0.009827:0.005125:0.010326:0.005851:0.010311:0.003024:0.009903:0.009782:0.007590
-:@0.475951:0.540473:0.480971:0.540473:0.480971:0.524690:0.475951:0.524690:0.005020
ers. There are, however, differences for some morbidity :@0.076189:0.554709:0.485128:0.554709:0.485128:0.538926:0.076189:0.538926:0.009827:0.004551:0.005866:0.004188:0.004823:0.006441:0.009223:0.009827:0.004551:0.009827:0.004823:0.010326:0.004551:0.009827:0.004188:0.004823:0.009223:0.009903:0.012564:0.009827:0.008376:0.009827:0.004551:0.004188:0.004823:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005866:0.004823:0.004747:0.009903:0.004551:0.004823:0.005866:0.009903:0.014182:0.009827:0.004823:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.004188
outcomes. First-line thiazides caused less HF and stroke :@0.076189:0.568944:0.485158:0.568944:0.485158:0.553162:0.076189:0.553162:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.005307:0.007333:0.003024:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005322:0.005125:0.009223:0.003024:0.010326:0.006426:0.003024:0.010357:0.009827:0.005866:0.005322:0.009782:0.010326:0.009192:0.005866:0.009827:0.010357:0.005322:0.003024:0.009827:0.005866:0.005866:0.005322:0.010326:0.007333:0.005322:0.010326:0.009223:0.010357:0.005322:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188
than first-line RAS inhibitors. First-line CCBs increased HF :@0.076189:0.583180:0.485158:0.583180:0.485158:0.567397:0.076189:0.567397:0.005125:0.009223:0.010326:0.009223:0.005261:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005277:0.009177:0.011188:0.007529:0.005277:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.005277:0.007333:0.003024:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.005277:0.012292:0.012292:0.008678:0.005866:0.005277:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.005277:0.010326:0.007333:0.004188
but  decreased  stroke  compared  to  first-line  RAS  inhi:@0.076189:0.597415:0.475936:0.597415:0.475936:0.581633:0.076189:0.581633:0.010311:0.009192:0.005125:0.004188:0.003220:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.004188:0.003220:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.003220:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.003220:0.005125:0.009903:0.004188:0.003220:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004188:0.003220:0.009177:0.011188:0.007529:0.004188:0.003220:0.003024:0.009223:0.009223:0.003024
-:@0.475936:0.597415:0.480955:0.597415:0.480955:0.581633:0.475936:0.581633:0.005020
bitors. The magnitude of the increase in HF exceeded :@0.076189:0.611651:0.485143:0.611651:0.485143:0.595868:0.076189:0.595868:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.005836:0.006441:0.009223:0.009827:0.005821:0.014182:0.010326:0.010175:0.009223:0.003024:0.005125:0.009192:0.010357:0.009827:0.005836:0.009903:0.004747:0.005836:0.005125:0.009223:0.009827:0.005821:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005836:0.003024:0.009223:0.005836:0.010326:0.007333:0.005836:0.009827:0.007257:0.009782:0.009827:0.009827:0.010357:0.009827:0.010357:0.004188
the decrease in stroke. Low-quality evidence suggests :@0.076189:0.625886:0.485128:0.625886:0.485128:0.610104:0.076189:0.610104:0.005125:0.009223:0.009827:0.005836:0.010357:0.009827:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.005836:0.003024:0.009223:0.005836:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.005821:0.006985:0.009903:0.012564:0.005020:0.010311:0.009192:0.010326:0.003024:0.003024:0.005125:0.008104:0.005836:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.005836:0.005866:0.009192:0.010175:0.010175:0.009827:0.005866:0.005125:0.005866:0.004188
that first-line RAS inhibitors reduced stroke and total CV :@0.076189:0.640122:0.485143:0.640122:0.485143:0.624339:0.076189:0.624339:0.005125:0.009223:0.010326:0.005125:0.004717:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004717:0.009177:0.011188:0.007529:0.004717:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004717:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004702:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004702:0.010326:0.009223:0.010357:0.004717:0.005125:0.009903:0.005125:0.010326:0.003024:0.004717:0.012292:0.010614:0.004188
events  compared  to  first-line  beta-blockers.  The  small :@0.076189:0.654357:0.485113:0.654357:0.485113:0.638575:0.076189:0.638575:0.009827:0.008376:0.009827:0.009223:0.005125:0.005866:0.004188:0.002752:0.009782:0.009903:0.014182:0.010311:0.010326:0.004551:0.009827:0.010357:0.004188:0.002752:0.005125:0.009903:0.004188:0.002752:0.003681:0.003681:0.004551:0.005866:0.005125:0.005020:0.003024:0.003024:0.009223:0.009827:0.004188:0.002752:0.010311:0.009827:0.005125:0.010326:0.005020:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004188:0.002752:0.006441:0.009223:0.009827:0.004188:0.002752:0.005866:0.014182:0.010326:0.003024:0.003024:0.004188
differences in effect on blood pressure between the dif-:@0.076189:0.668593:0.480925:0.668593:0.480925:0.652810:0.076189:0.652810:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005866:0.003750:0.003024:0.009223:0.003765:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003750:0.009903:0.009223:0.003750:0.010311:0.003024:0.009903:0.009903:0.010357:0.003750:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.003750:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.003750:0.005125:0.009223:0.009827:0.003750:0.010357:0.003024:0.004747:0.005020
ferent classes of drugs did not correlate with the differ-:@0.076189:0.682828:0.480955:0.682828:0.480955:0.667046:0.076189:0.667046:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.004974:0.009782:0.003024:0.010326:0.005866:0.005866:0.009827:0.005866:0.004989:0.009903:0.004747:0.004989:0.010357:0.004551:0.009192:0.010175:0.005866:0.004974:0.010357:0.003024:0.010357:0.004989:0.009223:0.009903:0.005125:0.004974:0.009782:0.009903:0.004551:0.004551:0.009827:0.003024:0.010326:0.005125:0.009827:0.004974:0.012564:0.003024:0.005125:0.009223:0.004989:0.005125:0.009223:0.009827:0.004974:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.005020
ences in the morbidity outcomes”.  This is perhaps not :@0.076189:0.697064:0.485132:0.697066:0.485132:0.681284:0.076189:0.681281:0.009827:0.009223:0.009782:0.009827:0.005866:0.005261:0.003024:0.009223:0.005261:0.005125:0.009223:0.009827:0.005261:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.005261:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.007318:0.004188:0.009726:0.005261:0.006441:0.009223:0.003024:0.005866:0.005261:0.003024:0.005866:0.005277:0.010311:0.009827:0.004551:0.009223:0.010326:0.010311:0.005866:0.005261:0.009223:0.009903:0.005125:-0.063578
18:@0.332054:0.691767:0.341770:0.691767:0.341770:0.682614:0.332054:0.682614:0.004858:0.004858
surprising as in patients with no comorbidities the big-:@0.076193:0.711302:0.480929:0.711302:0.480929:0.695519:0.076193:0.695519:0.005866:0.009192:0.004551:0.010311:0.004551:0.003024:0.005866:0.003024:0.009223:0.010175:0.006380:0.010326:0.005866:0.006380:0.003024:0.009223:0.006380:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.006380:0.012564:0.003024:0.005125:0.009223:0.006380:0.009223:0.009903:0.006380:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.003024:0.009827:0.005866:0.006380:0.005125:0.009223:0.009827:0.006380:0.010311:0.003024:0.010175:0.005020
gest risk factor is the blood pressure per se and RAAs :@0.076193:0.725537:0.485132:0.725537:0.485132:0.709755:0.076193:0.709755:0.010175:0.009827:0.005866:0.005125:0.006229:0.004551:0.003024:0.005866:0.007590:0.006244:0.004747:0.010326:0.009782:0.005125:0.009903:0.004536:0.006244:0.003024:0.005866:0.006244:0.005125:0.009223:0.009827:0.006229:0.010311:0.003024:0.009903:0.009903:0.010357:0.006244:0.010311:0.004551:0.009827:0.005866:0.005866:0.009192:0.004551:0.009827:0.006229:0.010311:0.009827:0.004551:0.006229:0.005866:0.009827:0.006244:0.010326:0.009223:0.010357:0.006244:0.009177:0.011188:0.011188:0.007529:-0.100861
blockers differentiate when the comorbid disease, i.e. :@0.076193:0.739773:0.485163:0.739773:0.485163:0.723990:0.076193:0.723990:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.006108:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.003024:0.010326:0.005125:0.009827:0.006108:0.012564:0.009223:0.009827:0.009223:0.006108:0.005125:0.009223:0.009827:0.006108:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.006108:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.006123:0.003024:0.004188:0.009827:0.004188:0.004188
underlying RAAs dependent pathology, is increased. :@0.076193:0.754008:0.467322:0.754008:0.467322:0.738226:0.076193:0.738226:0.009192:0.009223:0.010357:0.009827:0.004551:0.003024:0.008104:0.003024:0.009223:0.010175:0.004188:0.009177:0.011188:0.011188:0.007529:0.004188:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.004188:0.010311:0.010326:0.005125:0.009223:0.009903:0.003024:0.009903:0.010175:0.008104:0.004188:0.004188:0.003024:0.005866:0.004188:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.004188:0.004188
COnClusiOn:@0.076190:0.786992:0.198151:0.786992:0.198151:0.766827:0.076190:0.766827:0.014413:0.015522:0.013674:0.014413:0.008131:0.011826:0.009609:0.005174:0.015522:0.013674
The  development  of  RAAs  blockers  over  more  than :@0.076190:0.803006:0.485145:0.803006:0.485145:0.787223:0.076190:0.787223:0.006441:0.009223:0.009827:0.004188:0.004339:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.004188:0.004339:0.009903:0.004747:0.004188:0.004339:0.009177:0.011188:0.011188:0.007529:0.004188:0.004339:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.005866:0.004188:0.004339:0.009903:0.008376:0.009827:0.004551:0.004188:0.004339:0.014182:0.009903:0.004551:0.009827:0.004188:0.004339:0.005125:0.009223:0.010326:0.009223:0.004188
three decades transformed the way clinicians treat pa-:@0.076190:0.817241:0.480972:0.817241:0.480972:0.801459:0.076190:0.801459:0.005125:0.009223:0.004551:0.009827:0.009827:0.004158:0.010357:0.009827:0.009782:0.010326:0.010357:0.009827:0.005866:0.004173:0.005125:0.004551:0.010326:0.009223:0.005866:0.004747:0.009903:0.004551:0.014182:0.009827:0.010357:0.004158:0.005125:0.009223:0.009827:0.004158:0.012564:0.010326:0.008104:0.004173:0.009782:0.003024:0.003024:0.009223:0.003024:0.009782:0.003024:0.010326:0.009223:0.005866:0.004173:0.005125:0.004551:0.009827:0.010326:0.005125:0.004158:0.010311:0.010326:0.005020
tients suffering from diabetes, heart failure and ischae-:@0.076190:0.831477:0.480942:0.831477:0.480942:0.815694:0.076190:0.815694:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005186:0.005866:0.009192:0.004747:0.004747:0.009827:0.004551:0.003024:0.009223:0.010175:0.005171:0.004747:0.004551:0.009903:0.014182:0.005171:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.005186:0.009223:0.009827:0.010326:0.004551:0.005125:0.005171:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005186:0.010326:0.009223:0.010357:0.005186:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.005020
mic stroke,  and those  high-risk patients with multiple :@0.076190:0.845712:0.485130:0.845712:0.485130:0.829930:0.076190:0.829930:0.014182:0.003024:0.009782:0.008104:0.005866:0.005125:0.004551:0.009903:0.007590:0.009827:0.004188:0.004188:0.003901:0.010326:0.009223:0.010357:0.008104:0.005125:0.009223:0.009903:0.005866:0.009827:0.004188:0.003901:0.009223:0.003024:0.010175:0.009223:0.005020:0.004551:0.003024:0.005866:0.007590:0.008104:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.008104:0.012564:0.003024:0.005125:0.009223:0.008104:0.014182:0.009192:0.003024:0.005125:0.003024:0.010311:0.003024:0.009827:0.004188
metabolic and cardiovascular comorbidities. It further :@0.076190:0.859948:0.485145:0.859948:0.485145:0.844165:0.076190:0.844165:0.014182:0.009827:0.005125:0.010326:0.010311:0.009903:0.003024:0.003024:0.009782:0.006229:0.010326:0.009223:0.010357:0.006229:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.006229:0.009782:0.009903:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.003024:0.009827:0.005866:0.004188:0.006229:0.003417:0.005125:0.006229:0.004747:0.009192:0.004551:0.005125:0.009223:0.009827:0.004551:0.004188
seems as if there is little difference in most of the out-:@0.076190:0.874183:0.480942:0.874183:0.480942:0.858401:0.076190:0.858401:0.005866:0.009827:0.009827:0.014182:0.005866:0.006123:0.010326:0.005866:0.006123:0.003024:0.004747:0.006123:0.005125:0.009223:0.009827:0.004551:0.009827:0.006108:0.003024:0.005866:0.006123:0.003024:0.003024:0.005125:0.005125:0.003024:0.009827:0.006123:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.006108:0.003024:0.009223:0.006123:0.014182:0.009903:0.005866:0.005125:0.006123:0.009903:0.004747:0.006123:0.005125:0.009223:0.009827:0.006123:0.009903:0.009192:0.005125:0.005020
comes  between  the  two  drug  classes, i.e.  ACEIs and :@0.076190:0.888419:0.485100:0.888419:0.485100:0.872636:0.076190:0.872636:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.002767:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004188:0.002767:0.005125:0.009223:0.009827:0.004188:0.002767:0.005125:0.012564:0.009903:0.004188:0.002767:0.010357:0.004551:0.009192:0.010175:0.004188:0.002767:0.009782:0.003024:0.010326:0.005866:0.005866:0.009827:0.005866:0.004188:0.006970:0.003024:0.004188:0.009827:0.004188:0.004188:0.002767:0.011188:0.012292:0.008104:0.003417:0.005866:0.006970:0.010326:0.009223:0.010357:0.004188
ARBs, with the bulk of the evidence only in some cases :@0.076190:0.902654:0.485100:0.902654:0.485100:0.886872:0.076190:0.886872:0.011188:0.009177:0.008678:0.005866:0.004188:0.004838:0.012564:0.003024:0.005125:0.009223:0.004838:0.005125:0.009223:0.009827:0.004838:0.010311:0.009192:0.003024:0.007590:0.004838:0.009903:0.004747:0.004838:0.005125:0.009223:0.009827:0.004838:0.009827:0.008376:0.003024:0.010357:0.009827:0.009223:0.009782:0.009827:0.004838:0.009903:0.009223:0.003024:0.008104:0.004838:0.003024:0.009223:0.004838:0.005866:0.009903:0.014182:0.009827:0.004838:0.009782:0.010326:0.005866:0.009827:0.005866:0.004188
(such as diabetic retinopathy) swinging to favour ACEIs. :@0.076190:0.916890:0.485115:0.916890:0.485115:0.901107:0.076190:0.901107:0.005579:0.005866:0.009192:0.009782:0.009223:0.003765:0.010326:0.005866:0.003765:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003765:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.005579:0.003765:0.005866:0.012564:0.003024:0.009223:0.010175:0.003024:0.009223:0.010175:0.003765:0.005125:0.009903:0.003765:0.004747:0.010326:0.008376:0.009903:0.009192:0.004551:0.003765:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.004188
Combination RAAs blockade is  indicated in hyper-:@0.076190:0.931126:0.480942:0.931126:0.480942:0.915343:0.076190:0.915343:0.012292:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.009797:0.009177:0.011188:0.011188:0.007529:0.009797:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.009797:0.003024:0.005866:0.004188:0.005624:0.003024:0.009223:0.010357:0.003024:0.009782:0.010326:0.005125:0.009827:0.010357:0.009797:0.003024:0.009223:0.009797:0.009223:0.008104:0.010311:0.009827:0.004551:-0.365062
tension and heart failure when the combination with an :@0.076190:0.945361:0.485130:0.945361:0.485130:0.929578:0.076190:0.929578:0.005125:0.009827:0.009223:0.005866:0.003024:0.009903:0.009223:0.003795:0.010326:0.009223:0.010357:0.003810:0.009223:0.009827:0.010326:0.004551:0.005125:0.003795:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.003810:0.012564:0.009223:0.009827:0.009223:0.003795:0.005125:0.009223:0.009827:0.003795:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.003795:0.012564:0.003024:0.005125:0.009223:0.003795:0.010326:0.009223:0.004188
aldosterone antagonist is warranted, but the combina-:@0.519042:0.084925:0.923794:0.084925:0.923794:0.069142:0.519042:0.069142:0.010326:0.003024:0.010357:0.009903:0.005866:0.005125:0.009827:0.004551:0.009903:0.009223:0.009827:0.004657:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004672:0.003024:0.005866:0.004672:0.012564:0.010326:0.004551:0.004551:0.010326:0.009223:0.005125:0.009827:0.010357:0.004188:0.004657:0.010311:0.009192:0.005125:0.004672:0.005125:0.009223:0.009827:0.004672:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.010326:0.005020
tions ACEI plus ARB or either plus renin antagonist result :@0.519042:0.099034:0.927997:0.099034:0.927997:0.083251:0.519042:0.083251:0.005125:0.003024:0.009903:0.009223:0.005866:0.004778:0.011188:0.012292:0.008104:0.003417:0.004778:0.010311:0.003024:0.009192:0.005866:0.004793:0.011188:0.009177:0.008678:0.004778:0.009903:0.004551:0.004778:0.009827:0.003024:0.005125:0.009223:0.009827:0.004551:0.004778:0.010311:0.003024:0.009192:0.005866:0.004778:0.004551:0.009827:0.009223:0.003024:0.009223:0.004778:0.010326:0.009223:0.005125:0.010326:0.010175:0.009903:0.009223:0.003024:0.005866:0.005125:0.004778:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.004188
in increased side effects and inferiority to single RAAs :@0.519042:0.113142:0.927982:0.113142:0.927982:0.097359:0.519042:0.097359:0.003024:0.009223:0.006305:0.003024:0.009223:0.009782:0.004551:0.009827:0.010326:0.005866:0.009827:0.010357:0.006305:0.005866:0.003024:0.010357:0.009827:0.006320:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.005866:0.006305:0.010326:0.009223:0.010357:0.006305:0.003024:0.009223:0.004747:0.009827:0.004551:0.003024:0.009903:0.004551:0.003024:0.005125:0.008104:0.006305:0.005125:0.009903:0.006305:0.005866:0.003024:0.009223:0.010175:0.003024:0.009827:0.006320:0.009177:0.011188:0.011188:0.007529:0.258235
blockade. Most guidelines still recommend ACEIs as first :@0.519042:0.127251:0.928012:0.127251:0.928012:0.111468:0.519042:0.111468:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.004188:0.004173:0.013894:0.009903:0.005866:0.005125:0.004173:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004188:0.005866:0.005125:0.003024:0.003024:0.003039:0.004188:0.004551:0.009827:0.009782:0.009903:0.014182:0.014182:0.009827:0.009223:0.010357:0.004173:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.010326:0.005866:0.004188:0.003681:0.003681:0.004551:0.005866:0.005125:0.004188
line with ARBs if ACEIs are poorly tolerated.:@0.519042:0.141359:0.829693:0.141359:0.829693:0.125577:0.519042:0.125577:0.003024:0.003024:0.009223:0.009827:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.011188:0.009177:0.008678:0.005866:0.004188:0.003024:0.004747:0.004188:0.011188:0.012292:0.008104:0.003417:0.005866:0.004188:0.010326:0.004551:0.009827:0.004188:0.010311:0.009903:0.009903:0.004551:0.003024:0.008104:0.004188:0.005125:0.009903:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.004188
referenCes:@0.519047:0.174234:0.625485:0.174234:0.625485:0.154069:0.519047:0.154069:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1.:@0.519047:0.186128:0.528819:0.186128:0.528819:0.173853:0.519047:0.173853:0.006515:0.003257
Hypertension in adults: Diagnosis and management, NICE Clinical:@0.544247:0.186128:0.923812:0.186128:0.923812:0.173853:0.544247:0.173853:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.004269:0.002352:0.007173:0.004280:0.008032:0.008055:0.007150:0.002352:0.003986:0.004563:0.003257:0.004280:0.008749:0.002352:0.008032:0.007914:0.007173:0.007702:0.004563:0.002352:0.004563:0.004280:0.008032:0.007173:0.008055:0.004280:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.004269:0.008702:0.002658:0.009560:0.006303:0.004280:0.009560:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352
Guideline [CG127] published date: August 2011 Last updated: No-:@0.544247:0.197030:0.923812:0.197030:0.923812:0.184754:0.544247:0.184754:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.003716:0.004127:0.009560:0.010254:0.006515:0.006515:0.006515:0.004127:0.003716:0.006961:0.007150:0.008020:0.002352:0.002352:0.004563:0.007173:0.007644:0.008055:0.003716:0.008055:0.008032:0.003986:0.007644:0.003257:0.003704:0.008702:0.007150:0.007914:0.007150:0.004563:0.003986:0.003704:0.006515:0.006515:0.006515:0.006515:0.003716:0.005433:0.008032:0.004563:0.003986:0.003716:0.007150:0.008020:0.008055:0.008032:0.003986:0.007644:0.008055:0.003257:0.003704:0.008702:0.007702:0.003904
vember 2016:@0.544247:0.207931:0.617954:0.207931:0.617954:0.195656:0.544247:0.195656:0.006515:0.007644:0.011030:0.008020:0.007644:0.003540:0.003257:0.006515:0.006515:0.006515:0.006515
2.:@0.519047:0.218833:0.528819:0.218833:0.528819:0.206557:0.519047:0.206557:0.006515:0.003257
ACCF/AHA 2013. Guideline for the management of heart failure;:@0.544247:0.218833:0.923812:0.218833:0.923812:0.206557:0.544247:0.206557:0.008702:0.009560:0.009560:0.005703:0.005139:0.008702:0.008032:0.008702:0.004739:0.006515:0.006515:0.006515:0.006515:0.003257:0.004762:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004751:0.003692:0.007702:0.003540:0.004751:0.003986:0.007173:0.007644:0.004751:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.004739:0.007702:0.003692:0.004751:0.007173:0.007644:0.008032:0.003540:0.003986:0.004751:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257
Circulation:@0.544247:0.229734:0.606054:0.229734:0.606054:0.217459:0.544247:0.217459:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173
. 2013;128:1810-1852.:@0.606054:0.229734:0.723964:0.229734:0.723964:0.217459:0.606054:0.217459:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
3.:@0.519047:0.240636:0.528819:0.240636:0.528819:0.228360:0.519047:0.228360:0.006515:0.003257
Turgeon RD, :@0.544247:0.240636:0.617072:0.240636:0.617072:0.228360:0.544247:0.228360:0.005009:0.007150:0.003540:0.007914:0.007644:0.007702:0.007173:0.004292:0.007138:0.008749:0.003257:0.003257
et al:@0.618119:0.240636:0.644436:0.240636:0.644436:0.228360:0.618119:0.228360:0.007644:0.003986:0.004304:0.008032:0.002352
. Higher versus lower doses of ACE inhibitors, an-:@0.644436:0.240636:0.923824:0.240636:0.923824:0.228360:0.644436:0.228360:0.003257:0.004304:0.008032:0.002352:0.007914:0.007173:0.007644:0.003540:0.004304:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.004304:0.002352:0.007702:0.009772:0.007644:0.003540:0.004304:0.008055:0.007702:0.004563:0.007644:0.004563:0.004304:0.007702:0.003692:0.004304:0.008702:0.009560:0.006303:0.004304:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.003257:0.004304:0.008032:0.007173:0.003904
giotensin-2 receptor blockers and beta-blockers in heart failure with :@0.544247:0.251537:0.927070:0.251537:0.927070:0.239262:0.544247:0.239262:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.006515:0.002646:0.003540:0.007644:0.007608:0.007644:0.008020:0.003986:0.007702:0.003540:0.002634:0.008020:0.002352:0.007702:0.007608:0.005903:0.007644:0.003540:0.004563:0.002646:0.008032:0.007173:0.008055:0.002646:0.008020:0.007644:0.003986:0.008032:0.003904:0.008020:0.002352:0.007702:0.007608:0.005903:0.007644:0.003540:0.004563:0.002646:0.002352:0.007173:0.002646:0.007173:0.007644:0.008032:0.003540:0.003986:0.002646:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.002646:0.009772:0.002352:0.003986:0.007173:0.003257
reduced  ejection  fraction:  systematic review and meta-analysis.:@0.544247:0.262439:0.923801:0.262439:0.923801:0.250163:0.544247:0.250163:0.003540:0.007644:0.008055:0.007150:0.007608:0.007644:0.008055:0.003257:0.002187:0.007644:0.002387:0.007644:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.002187:0.003692:0.003540:0.008032:0.007608:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257:0.002199:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.005456:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.005456:0.008032:0.007173:0.008055:0.005456:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.061385
February 28, 2019; https://doi.org/10.1371/journal.pone.0212907:@0.544247:0.273340:0.904951:0.273340:0.904951:0.261065:0.544247:0.261065:0.005703:0.007644:0.008020:0.003540:0.007150:0.008032:0.003540:0.006303:0.003257:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.008055:0.007702:0.002352:0.003257:0.007702:0.003540:0.007914:0.005139:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.002387:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257:0.008020:0.007702:0.007173:0.007644:0.003257:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515
4.:@0.519047:0.284242:0.528819:0.284242:0.528819:0.271966:0.519047:0.271966:0.006515:0.003257
ATMOspHERE study; April 2016. :@0.544247:0.284242:0.724752:0.284242:0.724752:0.271966:0.544247:0.271966:0.008702:0.005009:0.010807:0.010219:0.005856:0.006961:0.008032:0.006303:0.007138:0.006303:0.004774:0.004563:0.003986:0.007150:0.008055:0.006303:0.003257:0.004774:0.008702:0.008020:0.003540:0.002352:0.002352:0.004774:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
N Eng J Med.:@0.726269:0.284242:0.806114:0.284242:0.806114:0.271966:0.726269:0.271966:0.008702:0.004774:0.006303:0.007173:0.007914:0.004774:0.005668:0.004774:0.010807:0.007644:0.008055:0.003257
 2016; 374:1521-1532:@0.806114:0.284242:0.923801:0.284242:0.923801:0.271966:0.806114:0.271966:0.004774:0.006515:0.006515:0.006515:0.006515:0.003257:0.004774:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515
DOI: 10.1056/NEJMoa1514859.:@0.544247:0.295143:0.715944:0.295143:0.715944:0.282868:0.544247:0.282868:0.008749:0.010219:0.002658:0.003257:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.008702:0.006303:0.005668:0.010807:0.007702:0.008032:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
5.:@0.519047:0.306045:0.528819:0.306045:0.528819:0.293769:0.519047:0.293769:0.006515:0.003257
Liu H, :@0.544247:0.306045:0.576738:0.306045:0.576738:0.293769:0.544247:0.293769:0.005433:0.002352:0.007150:0.003010:0.008032:0.003257:0.003257
et al:@0.576491:0.306045:0.601515:0.306045:0.601515:0.293769:0.576491:0.293769:0.007644:0.003986:0.003010:0.008032:0.002352
. Aliskiren for heart failure: A systematic review and meta-:@0.601515:0.306045:0.923812:0.306045:0.923812:0.293769:0.601515:0.293769:0.003257:0.003010:0.008702:0.002352:0.002352:0.004563:0.005903:0.002352:0.003540:0.007644:0.007173:0.002999:0.003692:0.007702:0.003540:0.002999:0.007173:0.007644:0.008032:0.003540:0.003986:0.002999:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003010:0.008702:0.002999:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003010:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003010:0.008032:0.007173:0.008055:0.003010:0.011030:0.007644:0.003986:0.008032:0.003904
analysis  of randomized  controlled  trials. :@0.544247:0.316946:0.782478:0.316946:0.782478:0.304671:0.544247:0.304671:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257:0.003116:0.007702:0.003692:0.006362:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.003093:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.003257:0.003093:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
Oncotarget:@0.785582:0.316946:0.853386:0.316946:0.853386:0.304671:0.785582:0.304671:0.010219:0.007173:0.007608:0.007702:0.003986:0.008032:0.003540:0.007914:0.007644:0.003986
. 2017;8(50)::@0.853386:0.316946:0.923801:0.316946:0.923801:0.304671:0.853386:0.304671:0.003257:0.006362:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.004339:0.006515:0.006515:0.004339:0.003257
88189-88198.:@0.544247:0.327847:0.616555:0.327847:0.616555:0.315572:0.544247:0.315572:0.006515:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257
6. :@0.519047:0.338749:0.532077:0.338749:0.532077:0.326474:0.519047:0.326474:0.006515:0.003257:0.353180
straus M and Hall A. :@0.544247:0.338749:0.657007:0.338749:0.657007:0.326474:0.544247:0.326474:0.005856:0.003986:0.003540:0.008032:0.007150:0.004563:0.002387:0.010807:0.002399:0.008032:0.007173:0.008055:0.002399:0.008032:0.008032:0.002352:0.002352:0.002399:0.008702:0.003257:0.003257
Prog Cardiovasc Dis.:@0.656137:0.338749:0.771918:0.338749:0.771918:0.326474:0.656137:0.326474:0.006961:0.003540:0.007702:0.007914:0.002387:0.009560:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.002399:0.008749:0.002352:0.004563:0.003257
 2016 Mar-Apr;58(5):473-82. :@0.771918:0.338749:0.927046:0.338749:0.927046:0.326474:0.771918:0.326474:0.002399:0.006515:0.006515:0.006515:0.006515:0.002399:0.010807:0.008032:0.003540:0.003904:0.008702:0.008020:0.003540:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257:0.003257
doi: 0.1016/j.pcad.2015.11.004. Epub 2015 Nov 14.:@0.544247:0.349650:0.826646:0.349650:0.826646:0.337375:0.544247:0.337375:0.008055:0.007702:0.002352:0.003257:0.003257:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.002387:0.003257:0.008020:0.007608:0.008032:0.008055:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.003257:0.006303:0.008020:0.007150:0.008020:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.008702:0.007702:0.006515:0.003257:0.006515:0.006515:0.003257
7.:@0.519047:0.360552:0.528819:0.360552:0.528819:0.348277:0.519047:0.348277:0.006515:0.003257
Bangalore,:@0.544247:0.360552:0.606642:0.360552:0.606642:0.348277:0.544247:0.348277:0.006750:0.008032:0.007173:0.007914:0.008032:0.002352:0.007702:0.003540:0.007644:0.003257
et al BMJ:@0.612251:0.360552:0.671988:0.360552:0.671988:0.348277:0.612251:0.348277:0.007644:0.003986:0.005621:0.008032:0.002352:0.008878:0.006750:0.010807:0.005668
. :@0.639885:0.360552:0.646400:0.360552:0.646400:0.348277:0.639885:0.348277:0.003257:0.003257
 2011; 342 doi:  https://doi.org/10.1136/bmj.:@0.671988:0.360552:0.923801:0.360552:0.923801:0.348277:0.671988:0.348277:0.005621:0.006515:0.006515:0.006515:0.006515:0.003257:0.005621:0.006515:0.006515:0.006515:0.005621:0.008055:0.007702:0.002352:0.003257:0.003257:0.002364:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.008055:0.007702:0.002352:0.003257:0.007702:0.003540:0.007914:0.005139:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.008020:0.011030:0.002387:0.003257
d2234 (published 26 April 2011): :@0.544247:0.371453:0.724917:0.371453:0.724917:0.359178:0.544247:0.359178:0.008055:0.006515:0.006515:0.006515:0.006526:0.003257:0.004339:0.006961:0.007150:0.008020:0.002352:0.002352:0.004563:0.007173:0.007644:0.008055:0.003257:0.006515:0.006515:0.003257:0.008702:0.008020:0.003540:0.002352:0.002352:0.003257:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.003257
BMJ:@0.724928:0.371453:0.748153:0.371453:0.748153:0.359178:0.724928:0.359178:0.006750:0.010807:0.005668
 2011;342:d2234.:@0.748153:0.371453:0.840898:0.371453:0.840898:0.359178:0.748153:0.359178:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.008055:0.006515:0.006515:0.006515:0.006515:0.003257
8.:@0.519047:0.382355:0.528819:0.382355:0.528819:0.370079:0.519047:0.370079:0.006515:0.003257
EsC Guidelines for the management of acute myocardial infarc-:@0.544247:0.382355:0.923801:0.382355:0.923801:0.370079:0.544247:0.370079:0.006303:0.005856:0.009560:0.004727:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.004727:0.003692:0.007702:0.003540:0.004715:0.003986:0.007173:0.007644:0.004715:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.004715:0.007702:0.003692:0.004727:0.008032:0.007608:0.007150:0.003986:0.007644:0.004727:0.011030:0.006303:0.007702:0.007608:0.008032:0.003540:0.008055:0.002352:0.008032:0.002352:0.004727:0.002352:0.007173:0.003692:0.008032:0.003540:0.007608:0.003904
tion  in patients  presenting  with  sT-segment  elevation. :@0.544247:0.393256:0.865381:0.393256:0.865381:0.380981:0.544247:0.380981:0.003986:0.002352:0.007702:0.007173:0.003257:0.002857:0.002352:0.007173:0.006127:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.002857:0.008020:0.003540:0.007644:0.004563:0.007644:0.007173:0.003986:0.002352:0.007173:0.007914:0.003257:0.002857:0.009772:0.002352:0.003986:0.007173:0.003257:0.002869:0.005856:0.005009:0.003904:0.004563:0.007644:0.007914:0.011030:0.007644:0.007173:0.003986:0.003257:0.002857:0.007644:0.002352:0.007644:0.006515:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
European :@0.868250:0.393256:0.927070:0.393256:0.927070:0.380981:0.868250:0.380981:0.006303:0.007150:0.003540:0.007702:0.008020:0.007644:0.008032:0.007173:0.003257
Heart Journal.:@0.544247:0.404158:0.623611:0.404158:0.623611:0.391882:0.544247:0.391882:0.008032:0.007644:0.008032:0.003540:0.003986:0.003257:0.005668:0.007702:0.007150:0.003540:0.007173:0.008032:0.002352:0.003257
 2017;39,119-177.:@0.623599:0.404158:0.718708:0.404158:0.718708:0.391882:0.623599:0.391882:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
9.:@0.519047:0.415059:0.528819:0.415059:0.528819:0.402784:0.519047:0.402784:0.006515:0.003257
Marre M, Leye A. :@0.544247:0.415059:0.645647:0.415059:0.645647:0.402784:0.544247:0.402784:0.010807:0.008032:0.003540:0.003540:0.007644:0.003845:0.010807:0.003257:0.003845:0.005433:0.007644:0.006303:0.007644:0.003845:0.008702:0.003257:0.003257
Diabetes Vasc Dis Res.:@0.646235:0.415059:0.775517:0.415059:0.775517:0.402784:0.646235:0.402784:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003857:0.008255:0.008032:0.004563:0.007608:0.003857:0.008749:0.002352:0.004563:0.003857:0.007138:0.007644:0.004563:0.003257
 2007;4:163-73doi:10.3132/:@0.775517:0.415059:0.923777:0.415059:0.923777:0.402784:0.775517:0.402784:0.003845:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.008055:0.007702:0.002352:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139
dvdr.2007.037.:@0.544247:0.425961:0.625786:0.425961:0.625786:0.413685:0.544247:0.413685:0.008055:0.006515:0.008055:0.003540:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257
10.  scheen AJ. Renin-angiotensin system inhibition prevents type 2 dia-:@0.519047:0.436862:0.923801:0.436862:0.923801:0.424587:0.519047:0.424587:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.007608:0.007173:0.007644:0.007644:0.007173:0.003093:0.008702:0.005668:0.003257:0.003093:0.007138:0.007644:0.007173:0.002352:0.007173:0.003904:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003093:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.003093:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.002352:0.007702:0.007173:0.003104:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.003093:0.003986:0.006303:0.008020:0.007644:0.003093:0.006515:0.003104:0.008055:0.002352:0.008032:-0.166379
betes mellitus. part 1. A meta-analysis of randomised clinical trials. :@0.544247:0.447764:0.927082:0.447764:0.927082:0.435488:0.544247:0.435488:0.008020:0.007644:0.003986:0.007644:0.004563:0.004069:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.004069:0.006961:0.008032:0.003540:0.003986:0.004057:0.006515:0.003257:0.004069:0.008702:0.004069:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004574:0.004069:0.007702:0.003692:0.004069:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004563:0.007644:0.008055:0.004069:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.004080:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
Diabetes Metab:@0.544247:0.458665:0.636981:0.458665:0.636981:0.446390:0.544247:0.446390:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.010807:0.007644:0.003986:0.008032:0.008020
. 2004;30:487-496:@0.636981:0.458665:0.732090:0.458665:0.732090:0.446390:0.636981:0.446390:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
11. Dagenais  GR, :@0.519047:0.469567:0.629208:0.469567:0.629208:0.457291:0.519047:0.457291:0.006515:0.006515:0.003257:0.008914:0.008749:0.008032:0.007914:0.007644:0.007173:0.008032:0.002352:0.004563:0.003257:0.003340:0.010254:0.007138:0.003257:0.003257
et al:@0.632536:0.469567:0.661134:0.469567:0.661134:0.457291:0.632536:0.457291:0.007644:0.003986:0.006585:0.008032:0.002352
. Angiotensin-converting-enzyme  inhibitors in:@0.661134:0.469567:0.923801:0.469567:0.923801:0.457291:0.661134:0.457291:0.003257:0.006585:0.008702:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.007608:0.007702:0.007173:0.006515:0.007644:0.003540:0.003986:0.002352:0.007173:0.007914:0.003904:0.007644:0.007173:0.004998:0.006303:0.011030:0.007644:0.003257:0.003304:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.006585:0.002352:0.007173
stable vascular disease without  left ventricular systolic dysfunc-:@0.544247:0.480468:0.923789:0.480468:0.923789:0.468193:0.544247:0.468193:0.004563:0.003986:0.008032:0.008020:0.002352:0.007644:0.006679:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.006679:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.006679:0.009772:0.002352:0.003986:0.007173:0.007702:0.007150:0.003986:0.003257:0.003410:0.002352:0.007644:0.003692:0.003986:0.006679:0.006515:0.007644:0.007173:0.003986:0.003540:0.002352:0.007608:0.007150:0.002352:0.008032:0.003540:0.006679:0.004563:0.006303:0.004563:0.003986:0.007702:0.002352:0.002352:0.007608:0.006679:0.008055:0.006303:0.004563:0.003692:0.007150:0.007173:0.007608:0.003904
tion  or  heart  failure:  A  combined  analysis of  three  trials. :@0.544247:0.491370:0.878481:0.491370:0.878481:0.479094:0.544247:0.479094:0.003986:0.002352:0.007702:0.007173:0.003257:0.002187:0.007702:0.003540:0.003257:0.002187:0.007173:0.007644:0.008032:0.003540:0.003986:0.003257:0.002187:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003257:0.002187:0.008702:0.003257:0.002187:0.007608:0.007702:0.011030:0.008020:0.002352:0.007173:0.007644:0.008055:0.003257:0.002187:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.005456:0.007702:0.003692:0.003257:0.002187:0.003986:0.007173:0.003540:0.007644:0.007644:0.003257:0.002187:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
Lancet.:@0.880680:0.491370:0.923812:0.491370:0.923812:0.479094:0.880680:0.479094:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257
2006;368:581-8:@0.544247:0.502271:0.626327:0.502271:0.626327:0.489996:0.544247:0.489996:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515
12. Dahlöf B, :@0.519047:0.513172:0.598657:0.513172:0.598657:0.500897:0.519047:0.500897:0.006515:0.006515:0.003257:0.008914:0.008749:0.008032:0.007173:0.002352:0.007702:0.003692:0.003445:0.006750:0.003257:0.058187
et al:@0.598857:0.513172:0.624316:0.513172:0.624316:0.500897:0.598857:0.500897:0.007644:0.003986:0.003445:0.008032:0.002352
. prevention of cardiovascular events with an antihy-:@0.624316:0.513172:0.923801:0.513172:0.923801:0.500897:0.624316:0.500897:0.003257:0.003457:0.006961:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003434:0.007702:0.003692:0.003445:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003457:0.007644:0.006515:0.007644:0.007173:0.003986:0.004563:0.003445:0.009772:0.002352:0.003986:0.007173:0.003445:0.008032:0.007173:0.003445:0.008032:0.007173:0.003986:0.002352:0.007173:0.006303:0.003904
pertensive regimen of amlodipine adding perindopril as required:@0.544259:0.524074:0.923824:0.524074:0.923824:0.511799:0.544259:0.511799:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.004892:0.003540:0.007644:0.007914:0.002352:0.011030:0.007644:0.007173:0.004880:0.007702:0.003692:0.004880:0.008032:0.011030:0.002352:0.007702:0.008055:0.002352:0.008020:0.002352:0.007173:0.007644:0.004892:0.008032:0.008055:0.008055:0.002352:0.007173:0.007914:0.004892:0.008020:0.007644:0.003540:0.002352:0.007173:0.008055:0.007702:0.008020:0.003540:0.002352:0.002352:0.004892:0.008032:0.004563:0.004892:0.003540:0.007644:0.008020:0.007150:0.002352:0.003540:0.007644:0.008055
versus  atenolol  adding  bendroflumethiazide  as  required,  in  the :@0.544259:0.534975:0.927082:0.534975:0.927082:0.522700:0.544259:0.522700:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.003257:0.003422:0.008032:0.003986:0.007644:0.007173:0.007702:0.002352:0.007702:0.002352:0.003257:0.003410:0.008032:0.008055:0.008055:0.002352:0.007173:0.007914:0.003257:0.003422:0.008020:0.007644:0.007173:0.008055:0.003540:0.007702:0.002852:0.002852:0.007150:0.011030:0.007632:0.003986:0.007173:0.002352:0.008032:0.004998:0.002352:0.008055:0.007644:0.003257:0.003410:0.008032:0.004563:0.003257:0.003422:0.003540:0.007644:0.008020:0.007150:0.002352:0.003540:0.007644:0.008055:0.003257:0.003257:0.003410:0.002352:0.007173:0.003257:0.003410:0.003986:0.007173:0.007644:0.003257
Anglo-scandinavian Cardiac Outcomes Trial-Blood pressure Lower-:@0.544259:0.545877:0.923824:0.545877:0.923824:0.533601:0.544259:0.533601:0.008702:0.007173:0.007914:0.002352:0.007702:0.003904:0.005856:0.007608:0.008032:0.007173:0.008055:0.002352:0.007173:0.008032:0.006515:0.002352:0.008032:0.007173:0.003010:0.009560:0.008032:0.003540:0.008055:0.002352:0.008032:0.007608:0.003010:0.010219:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003010:0.005009:0.003540:0.002352:0.008032:0.002352:0.003904:0.006750:0.002352:0.007702:0.007702:0.008055:0.003010:0.006961:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.002999:0.005433:0.007702:0.009772:0.007644:0.003540:0.003904
ing Arm (AsCOT-BpLA): A multicentre randomised controlled trial.:@0.544259:0.556778:0.923824:0.556778:0.923824:0.544503:0.544259:0.544503:0.002352:0.007173:0.007914:0.004704:0.008702:0.003540:0.011030:0.004704:0.004339:0.008702:0.005856:0.009560:0.010219:0.005009:0.003904:0.006750:0.006961:0.005433:0.008702:0.004339:0.003257:0.004692:0.008702:0.004692:0.011030:0.007150:0.002352:0.003986:0.002352:0.007608:0.007644:0.007173:0.003986:0.003540:0.007644:0.004692:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004563:0.007644:0.008055:0.004704:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.002352:0.007644:0.008055:0.004692:0.003986:0.003540:0.002352:0.008032:0.002352:-0.324083
Lancet.:@0.544259:0.567680:0.587392:0.567680:0.587392:0.555404:0.544259:0.555404:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257
 2005;366:895-906:@0.587380:0.567680:0.685746:0.567680:0.685746:0.555404:0.587380:0.555404:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
13. Izzo JL, Zion As. Value of angiotensin receptor blocker therapy in:@0.519059:0.578581:0.923801:0.578581:0.923801:0.566306:0.519059:0.566306:0.006515:0.006515:0.003257:0.008914:0.002658:0.004998:0.004998:0.007702:0.004657:0.005668:0.005433:0.003257:0.004657:0.005644:0.002352:0.007702:0.007173:0.004657:0.008702:0.005856:0.003257:0.004657:0.008255:0.008032:0.002352:0.007150:0.007644:0.004668:0.007702:0.003692:0.004657:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.004657:0.003540:0.007644:0.007608:0.007644:0.008020:0.003986:0.007702:0.003540:0.004657:0.008020:0.002352:0.007702:0.007608:0.005903:0.007644:0.003540:0.004657:0.003986:0.007173:0.007644:0.003540:0.008032:0.008020:0.006303:0.004657:0.002352:0.007173
diabetes. :@0.544259:0.589483:0.601068:0.589483:0.601068:0.577207:0.544259:0.577207:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
J Clin Hypertens:@0.601068:0.589483:0.691591:0.589483:0.691591:0.577207:0.601068:0.577207:0.005668:0.003257:0.009560:0.002352:0.002352:0.007173:0.003257:0.008032:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563
 (Greenwich). 2011;13:290-295:@0.691591:0.589483:0.861794:0.589483:0.861794:0.577207:0.691591:0.577207:0.003257:0.004339:0.010254:0.003540:0.007644:0.007644:0.007173:0.009772:0.002352:0.007608:0.007173:0.004339:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515
14. Barnett  AH, :@0.519059:0.600384:0.613686:0.600384:0.613686:0.588109:0.519059:0.588109:0.006515:0.006515:0.003257:0.008914:0.006750:0.008032:0.003540:0.007173:0.007644:0.003986:0.003986:0.003257:0.001811:0.008702:0.008032:0.003257:0.003257
et  al:@0.615508:0.600384:0.642590:0.600384:0.642590:0.588109:0.615508:0.588109:0.007644:0.003986:0.003257:0.001811:0.008032:0.002352
. Angiotensin-receptor  blockade versus convert-:@0.642590:0.600384:0.923824:0.600384:0.923824:0.588109:0.642590:0.588109:0.003257:0.005080:0.008702:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.003540:0.007644:0.007608:0.007644:0.008020:0.003986:0.007702:0.003540:0.003257:0.001799:0.008020:0.002352:0.007702:0.007608:0.005903:0.008032:0.008055:0.007644:0.005080:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.005080:0.007608:0.007702:0.007173:0.006515:0.007644:0.003540:0.003986:0.003904
ing-enzyme inhibition in type 2 diabetes and nephropathy. :@0.544259:0.611286:0.879656:0.611286:0.879656:0.599010:0.544259:0.599010:0.002352:0.007173:0.007914:0.003904:0.007644:0.007173:0.004998:0.006303:0.011030:0.007644:0.003104:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.002352:0.007702:0.007173:0.003116:0.002352:0.007173:0.003116:0.003986:0.006303:0.008020:0.007644:0.003116:0.006515:0.003116:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003116:0.008032:0.007173:0.008055:0.003116:0.007173:0.007644:0.008020:0.007173:0.003540:0.007702:0.008020:0.008032:0.003986:0.007173:0.006303:0.003257:0.003257
N Engl J :@0.879492:0.611286:0.927082:0.611286:0.927082:0.599010:0.879492:0.599010:0.008702:0.003104:0.006303:0.007173:0.007914:0.002352:0.003116:0.005668:0.003257
Med.:@0.544259:0.622187:0.574022:0.622187:0.574022:0.609912:0.544259:0.609912:0.010807:0.007644:0.008055:0.003257
 2004;351:1952-61]:@0.574022:0.622187:0.676515:0.622187:0.676515:0.609912:0.574022:0.609912:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.004127
15. Corbo JM, :@0.519059:0.633089:0.607442:0.633089:0.607442:0.620813:0.519059:0.620813:0.006397:0.006397:0.003257:0.009149:0.009443:0.007585:0.003422:0.007902:0.007585:0.004610:0.005550:0.010689:0.003140:-0.107630
et al:@0.608794:0.633089:0.635064:0.633089:0.635064:0.620813:0.608794:0.620813:0.007526:0.003869:0.004610:0.007914:0.002352
. ACE inhibitors or ARBs to prevent CKD in patients:@0.634946:0.633089:0.923789:0.633089:0.923789:0.620813:0.634946:0.620813:0.003140:0.004610:0.008584:0.009443:0.006185:0.004610:0.002234:0.007056:0.007056:0.002234:0.007902:0.002234:0.003869:0.007585:0.003422:0.004445:0.004610:0.007585:0.003422:0.004610:0.008584:0.007020:0.006632:0.004445:0.004610:0.003869:0.007585:0.004610:0.007902:0.003422:0.007526:0.006397:0.007526:0.007056:0.003869:0.004610:0.009443:0.006832:0.008631:0.004610:0.002234:0.007056:0.004610:0.007902:0.007914:0.003869:0.002234:0.007526:0.007056:0.003869:0.004563
with microalbuminuria. :@0.544259:0.643990:0.673928:0.643990:0.673928:0.631715:0.544259:0.631715:0.009654:0.002234:0.003869:0.007056:0.002928:0.010913:0.002234:0.007491:0.003422:0.007585:0.007914:0.002234:0.007902:0.007032:0.010913:0.002234:0.007056:0.007032:0.003422:0.002234:0.007914:0.003140:0.003257
Am Fam Phys.:@0.673611:0.643990:0.751163:0.643990:0.751163:0.631715:0.673611:0.631715:0.008584:0.010913:0.002928:0.005586:0.007914:0.010913:0.002928:0.006844:0.007056:0.006185:0.004445:0.003257
 2016; 94 (8) (ww.aafp.org/afp):@0.751046:0.643990:0.923789:0.643990:0.923789:0.631715:0.751046:0.631715:0.002928:0.006397:0.006397:0.006397:0.006397:0.003140:0.002928:0.006397:0.006397:0.002928:0.004222:0.006397:0.004222:0.002928:0.004222:0.009654:0.009654:0.003140:0.007914:0.007914:0.003575:0.007902:0.003140:0.007585:0.003422:0.007796:0.005021:0.007914:0.003575:0.007902:0.004339
16. Batra G, :@0.519059:0.654892:0.595518:0.654892:0.595518:0.642616:0.519059:0.642616:0.006515:0.006515:0.003257:0.008914:0.006750:0.008032:0.003986:0.003540:0.008032:0.004151:0.010254:0.003257:0.003257
et al:@0.596411:0.654892:0.622564:0.654892:0.622564:0.642616:0.596411:0.642616:0.007644:0.003986:0.004139:0.008032:0.002352
. ACEIs and ARBs are associated with improved out-:@0.622564:0.654892:0.923848:0.654892:0.923848:0.642616:0.622564:0.642616:0.003257:0.004139:0.008702:0.009560:0.006303:0.002658:0.004563:0.004151:0.008032:0.007173:0.008055:0.004151:0.008702:0.007138:0.006750:0.004563:0.004151:0.008032:0.003540:0.007644:0.004151:0.008032:0.004563:0.004563:0.007702:0.007608:0.002352:0.008032:0.003986:0.007644:0.008055:0.004151:0.009772:0.002352:0.003986:0.007173:0.004151:0.002352:0.011030:0.008020:0.003540:0.007702:0.006515:0.007644:0.008055:0.004151:0.007702:0.007150:0.003986:0.003904
comes but do not prevent new-onset AF after MI. :@0.544259:0.665793:0.823330:0.665793:0.823330:0.653518:0.544259:0.653518:0.007608:0.007702:0.011030:0.007644:0.004563:0.002681:0.008020:0.007150:0.003986:0.002681:0.008055:0.007702:0.002681:0.007173:0.007702:0.003986:0.002669:0.008020:0.003540:0.007644:0.006515:0.007644:0.007173:0.003986:0.002669:0.007173:0.007644:0.009772:0.003904:0.007702:0.007173:0.004563:0.007644:0.003986:0.002669:0.008702:0.005703:0.002669:0.008032:0.003692:0.003986:0.007644:0.003540:0.002669:0.010807:0.002658:0.003257:0.003257
J Am Heart Assoc.:@0.822753:0.665793:0.923824:0.665793:0.923824:0.653518:0.822753:0.653518:0.005668:0.002681:0.008702:0.011030:0.002681:0.008032:0.007644:0.008032:0.003540:0.003986:0.002681:0.008702:0.004563:0.004563:0.007702:0.007608:0.003257
 :@0.923824:0.665793:0.927082:0.665793:0.927082:0.653518:0.923824:0.653518:0.003257
2017; 6: e005165 DOI: 10.1161/JAHA.116.005165]:@0.544259:0.676694:0.815851:0.676694:0.815851:0.664419:0.544259:0.664419:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.003257:0.003257:0.007644:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257:0.008749:0.010219:0.002658:0.003257:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.005668:0.008702:0.008032:0.008702:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.004127
17. Wang B, :@0.519059:0.687596:0.596411:0.687596:0.596411:0.675321:0.519059:0.675321:0.006515:0.006515:0.003257:0.008914:0.011289:0.008032:0.007173:0.007914:0.004480:0.006750:0.003257:-0.167979
et al:@0.597634:0.687596:0.624128:0.687596:0.624128:0.675321:0.597634:0.675321:0.007644:0.003986:0.004480:0.008032:0.002352
. Effects of RAs inhibitors on diabetic retinopathy: A:@0.624128:0.687596:0.923812:0.687596:0.923812:0.675321:0.624128:0.675321:0.003257:0.004480:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.004563:0.004480:0.007702:0.003692:0.004480:0.007138:0.008702:0.005856:0.004480:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.004480:0.007702:0.007173:0.004480:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.002352:0.007608:0.004492:0.003540:0.007644:0.003986:0.002352:0.007173:0.007702:0.008020:0.008032:0.003986:0.007173:0.006303:0.003257:0.004469:0.008702
systematic review and meta-analysis.:@0.544259:0.698497:0.758971:0.698497:0.758971:0.686222:0.544259:0.686222:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.004233:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.004233:0.008032:0.007173:0.008055:0.004233:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003257
 Lancet.:@0.758983:0.698497:0.806349:0.698497:0.806349:0.686222:0.758983:0.686222:0.004233:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986:0.003257
 2015; 3 (4): 263-274,:@0.806338:0.698497:0.923801:0.698497:0.923801:0.686222:0.806338:0.686222:0.004233:0.006515:0.006515:0.006515:0.006515:0.003257:0.004233:0.006515:0.004233:0.004339:0.006515:0.004339:0.003257:0.004233:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
2015DOI:https://doi.org/10.1016/s2213-8587(14)70256-6]\]:@0.544259:0.709399:0.871613:0.709399:0.871613:0.697124:0.544259:0.697124:0.006515:0.006515:0.006515:0.006515:0.008749:0.010219:0.002658:0.003269:0.007173:0.003986:0.003986:0.008020:0.004563:0.003257:0.005139:0.005139:0.008055:0.007702:0.002352:0.003257:0.007702:0.003540:0.007914:0.005139:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.005856:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.006515:0.003904:0.006562:0.004127:0.007114:0.004127
18. Chen YJ, :@0.519059:0.720300:0.599869:0.720300:0.599869:0.708025:0.519059:0.708025:0.006515:0.006515:0.003257:0.008914:0.009560:0.007173:0.007644:0.007173:0.004915:0.006961:0.005668:0.003257:0.003257
et al:@0.601527:0.720300:0.628455:0.720300:0.628455:0.708025:0.601527:0.708025:0.007644:0.003986:0.004915:0.008032:0.002352
. First-line drugs inhibiting the renin angiotensin sys-:@0.628455:0.720300:0.923836:0.720300:0.923836:0.708025:0.628455:0.708025:0.003257:0.004915:0.005703:0.002352:0.003540:0.004563:0.003986:0.003904:0.002352:0.002352:0.007173:0.007644:0.004915:0.008055:0.003540:0.007150:0.007914:0.004563:0.004915:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.002352:0.007173:0.007914:0.004915:0.003986:0.007173:0.007644:0.004915:0.003540:0.007644:0.007173:0.002352:0.007173:0.004915:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.004915:0.004563:0.006303:0.004563:0.003904
tem versus other first-line antihypertensive drug classes for hyper:@0.544259:0.731202:0.919920:0.731202:0.919920:0.718926:0.544259:0.718926:0.003986:0.007644:0.011030:0.005009:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.005009:0.007702:0.003986:0.007173:0.007644:0.003540:0.004998:0.002863:0.002863:0.003540:0.004563:0.003986:0.003904:0.002352:0.002352:0.007173:0.007644:0.005009:0.008032:0.007173:0.003986:0.002352:0.007173:0.006303:0.008020:0.007644:0.003540:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.005009:0.008055:0.003540:0.007150:0.007914:0.004998:0.007608:0.002352:0.008032:0.004563:0.004563:0.007644:0.004563:0.005021:0.003692:0.007702:0.003540:0.004998:0.007173:0.006303:0.008020:0.007644:0.003540
-:@0.919920:0.731202:0.923824:0.731202:0.923824:0.718926:0.919920:0.718926:0.003904
tension. :@0.544259:0.742103:0.591367:0.742103:0.591367:0.729828:0.544259:0.729828:0.003986:0.007644:0.007173:0.004563:0.002352:0.007702:0.007173:0.003257:0.003257
Cochrane Data base of Systematic Reviews :@0.591402:0.742103:0.844978:0.742103:0.844978:0.729828:0.591402:0.729828:0.009560:0.007702:0.007608:0.007173:0.003540:0.008032:0.007173:0.007644:0.003281:0.008749:0.008032:0.003986:0.008032:0.003293:0.008020:0.008032:0.004563:0.007644:0.003293:0.007702:0.003692:0.003293:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003293:0.007138:0.007644:0.006515:0.002352:0.007644:0.009772:0.004563:0.003257
2018, Issue 11. :@0.845049:0.742103:0.927082:0.742103:0.927082:0.729828:0.845049:0.729828:0.006515:0.006515:0.006515:0.006515:0.003257:0.003304:0.002658:0.004563:0.004563:0.007150:0.007644:0.003293:0.006515:0.006515:0.003257:0.003257
Art.No.:  CD008170.  DOI: 10.1002/14651858.CD008170.pub3.  www.:@0.544271:0.753005:0.923836:0.753005:0.923836:0.740729:0.544271:0.740729:0.008702:0.003540:0.003986:0.003257:0.008702:0.007702:0.003257:0.003257:0.003257:0.002352:0.009560:0.008749:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.002387:0.008749:0.010219:0.002658:0.003257:0.005633:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.005139:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257:0.009560:0.008749:0.006515:0.006515:0.006515:0.006515:0.006515:0.006515:0.003257:0.008020:0.007150:0.008020:0.006515:0.003257:0.003257:0.002434:0.009772:0.009772:0.009772:0.003257
cochranelibrary.com].:@0.544271:0.763906:0.671859:0.763906:0.671859:0.751631:0.544271:0.751631:0.007608:0.007702:0.007608:0.007173:0.003540:0.008032:0.007173:0.007644:0.002352:0.002352:0.008020:0.003540:0.008032:0.003540:0.006303:0.003257:0.007608:0.007702:0.011018:0.004127:0.003257
References: 1.:@-0.971209:0.779520:-0.866822:0.779520:-0.866822:0.766556:-0.971209:0.766556:0.011025:0.008490:0.005085:0.008490:0.005940:0.008490:0.009330:0.008490:0.008490:0.008490:0.005085:0.004245:0.008490:0.004245
 IMS Data May 2019    :@-0.866807:0.779547:-0.710638:0.779547:-0.710638:0.766635:-0.866807:0.766635:0.004245:0.004245:0.012720:0.010185:0.004245:0.011025:0.008490:0.004245:0.008490:0.004245:0.012720:0.008490:0.007635:0.004245:0.008490:0.008490:0.008490:0.008490:0.004245:0.004245:0.004245:0.004245
2.:@-0.710638:0.779520:-0.697903:0.779520:-0.697903:0.766556:-0.710638:0.766556:0.008490:0.004245
 H.G. Dammann, F. Burkhardt & N. Wolf.  Enteric coating of aspirin significantly decreases :@-0.697903:0.779547:-0.086300:0.779547:-0.086300:0.766635:-0.697903:0.766635:0.004245:0.011025:0.004245:0.011880:0.004245:0.004245:0.011025:0.008490:0.012720:0.012720:0.008490:0.008490:0.008490:0.004245:0.004245:0.007635:0.004245:0.004245:0.010185:0.008490:0.005085:0.007635:0.008490:0.008490:0.005085:0.008490:0.004245:0.004245:0.010185:0.004245:0.011025:0.004245:0.004245:0.014140:0.008490:0.003390:0.004245:0.004245:0.004245:0.004245:0.010185:0.008490:0.004245:0.008490:0.005085:0.003390:0.007635:0.004245:0.007635:0.008490:0.008490:0.004245:0.003390:0.008490:0.008490:0.004245:0.008490:0.004245:0.004245:0.008490:0.007635:0.008490:0.003390:0.005085:0.003390:0.008490:0.004245:0.007635:0.003390:0.008490:0.008490:0.003390:0.003818:0.003818:0.007635:0.008490:0.008490:0.004245:0.003390:0.007635:0.004245:0.008490:0.008490:0.007635:0.005085:0.008490:0.008490:0.007635:0.008490:0.007635:0.004245
gastroduodenal mucosal lesions.  Ailment Pharmacol Ther 1999; 13: 1109-1114.:@-0.971209:0.793540:-0.431590:0.793540:-0.431590:0.780629:-0.971209:0.780629:0.008490:0.008490:0.007635:0.004245:0.005085:0.008490:0.008490:0.008490:0.008490:0.008490:0.008490:0.008490:0.008490:0.003390:0.004245:0.012720:0.008490:0.007635:0.008490:0.007635:0.008490:0.003390:0.004245:0.003390:0.008490:0.007635:0.003390:0.008490:0.008490:0.007635:0.004245:0.004245:0.003436:0.010185:0.003390:0.003390:0.012720:0.008490:0.008490:0.004245:0.004245:0.010185:0.008490:0.008490:0.005085:0.012720:0.008490:0.007635:0.008490:0.003390:0.003986:0.009330:0.008490:0.008490:0.005085:0.004245:0.008490:0.008490:0.008490:0.008490:0.004245:0.004245:0.008490:0.008490:0.004245:0.004245:0.007376:0.008490:0.008490:0.008490:0.005085:0.007376:0.007360:0.008490:0.008490:0.004245
STILL THE NO 1:@-0.758181:0.553694:-0.449319:0.553694:-0.449319:0.519429:-0.758181:0.519429:0.026922:0.024743:0.011221:0.024218:0.024662:0.011221:0.024501:0.029021:0.026922:0.011221:0.029143:0.031403:0.011221:0.022442
 low dose :@-0.449319:0.553694:-0.255654:0.553694:-0.255654:0.519429:-0.449319:0.519429:0.011221:0.010939:0.024016:0.031403:0.011221:0.024501:0.024339:0.022361:0.022442:0.011221
aspirin prescribed by cardiologists:@-0.850937:0.598912:-0.185543:0.598912:-0.185543:0.564646:-0.850937:0.564646:0.022281:0.022200:0.024541:0.010777:0.015217:0.010737:0.024662:0.011221:0.024581:0.015701:0.022846:0.022200:0.022321:0.015217:0.010858:0.024864:0.023048:0.024662:0.011221:0.023774:0.022442:0.011221:0.022483:0.022321:0.015540:0.024339:0.010939:0.024420:0.010939:0.024622:0.024258:0.010898:0.022240:0.013360:0.022442
1:@-0.187189:0.583432:-0.174106:0.583432:-0.174106:0.563455:-0.187189:0.563455:0.013084
Enteric coated shell provides :@-0.791108:0.689316:-0.222869:0.689316:-0.222869:0.655050:-0.791108:0.655050:0.026680:0.024258:0.013078:0.022846:0.015217:0.010979:0.022442:0.011221:0.022281:0.024501:0.022240:0.013078:0.023048:0.024662:0.011221:0.022119:0.024541:0.022805:0.010696:0.011221:0.011221:0.024581:0.015459:0.023532:0.022039:0.011060:0.024702:0.022846:0.022442:0.011221
protection from gastric discomfort:@-0.847779:0.734534:-0.190780:0.734534:-0.190780:0.700268:-0.847779:0.700268:0.024581:0.015459:0.024299:0.013078:0.022967:0.022563:0.013401:0.010979:0.024380:0.024662:0.011221:0.013037:0.015459:0.024460:0.035883:0.011221:0.024581:0.022281:0.022281:0.013360:0.015217:0.010979:0.022442:0.011221:0.024339:0.010898:0.022200:0.022281:0.024460:0.035520:0.013037:0.024420:0.016388:0.013441
2:@-0.190374:0.719054:-0.177290:0.719054:-0.177290:0.699077:-0.190374:0.699077:0.013084
For full prescribing information refer to package insert approved by the medicines regulatory authority. Further information is available on :@-0.971209:0.857597:-0.080338:0.857597:-0.080338:0.845159:-0.971209:0.845159:0.008988:0.008179:0.004899:0.004090:0.004090:0.008179:0.003266:0.003266:0.004090:0.008179:0.004899:0.008179:0.007355:0.007355:0.004899:0.003266:0.008179:0.003266:0.008179:0.008179:0.004090:0.003266:0.008179:0.004090:0.008179:0.004899:0.012254:0.008179:0.004090:0.003266:0.008179:0.008179:0.004090:0.004899:0.008179:0.004090:0.008179:0.004899:0.004090:0.004090:0.008179:0.004090:0.008179:0.008179:0.007355:0.007355:0.008179:0.008179:0.008179:0.004090:0.003266:0.008179:0.007355:0.008179:0.004899:0.004090:0.004090:0.008179:0.008179:0.008179:0.004899:0.008179:0.007355:0.008179:0.008179:0.004090:0.008179:0.007355:0.004090:0.004090:0.008179:0.008179:0.004090:0.012254:0.008179:0.008179:0.003266:0.007355:0.003266:0.008179:0.008179:0.007355:0.004090:0.004899:0.008179:0.008179:0.008179:0.003266:0.008179:0.004090:0.008179:0.004899:0.007355:0.004090:0.008179:0.008179:0.004090:0.008179:0.008179:0.004899:0.003266:0.004090:0.006267:0.004090:0.004090:0.008988:0.008179:0.004899:0.004090:0.008179:0.008179:0.004899:0.004090:0.003266:0.008179:0.004090:0.008179:0.004899:0.012254:0.008179:0.004090:0.003266:0.008179:0.008179:0.004090:0.003266:0.007355:0.004090:0.008179:0.007355:0.008179:0.003266:0.003266:0.008179:0.008179:0.003266:0.008179:0.004090:0.008179:0.008179:0.004090
request to the holder of registration. Litha Pharma (Pty) Ltd. Reg. no.: 1994/008717/07. 106 16th Rd, Midrand. 087 742-1860. :@-0.971209:0.872571:-0.152654:0.872571:-0.152654:0.860133:-0.971209:0.860133:0.004899:0.008179:0.008179:0.008179:0.008179:0.007355:0.004090:0.004090:0.004090:0.008179:0.004090:0.004090:0.008179:0.008179:0.004090:0.008179:0.008179:0.003266:0.008179:0.008179:0.004899:0.004090:0.008179:0.004090:0.004090:0.004899:0.008179:0.008179:0.003266:0.007355:0.004090:0.004899:0.008179:0.004090:0.003266:0.008179:0.008179:0.004090:0.004104:0.008179:0.003266:0.004090:0.008179:0.008179:0.004090:0.009812:0.008179:0.008179:0.004899:0.012254:0.008179:0.004090:0.004899:0.009812:0.004090:0.007355:0.004899:0.004090:0.008179:0.004090:0.008179:0.004090:0.004090:0.010621:0.008179:0.008179:0.004090:0.004090:0.008179:0.008179:0.004090:0.004090:0.004090:0.008179:0.008179:0.008179:0.008179:0.004090:0.008179:0.008179:0.008179:0.008179:0.008179:0.008179:0.004090:0.008179:0.008179:0.004104:0.004090:0.008179:0.008179:0.008179:0.004090:0.008179:0.008179:0.004090:0.008179:0.004090:0.010621:0.008179:0.004090:0.004090:0.012254:0.003266:0.008179:0.004899:0.008179:0.008179:0.008179:0.004090:0.004090:0.008179:0.008179:0.008179:0.004090:0.008179:0.008179:0.008179:0.004899:0.008179:0.008179:0.008179:0.008179:0.004090:0.004090
www.lithahealthcare.co.za:@-0.971209:0.887545:-0.801158:0.887545:-0.801158:0.875107:-0.971209:0.875107:0.010621:0.010621:0.009812:0.004090:0.003266:0.003266:0.004090:0.008179:0.008179:0.008179:0.008179:0.008179:0.003266:0.004090:0.008179:0.007355:0.008179:0.004899:0.008179:0.004090:0.007355:0.008179:0.004090:0.007355:0.008179
LP 2788 07/2019:@-0.971209:0.907473:-0.859426:0.907473:-0.859426:0.895035:-0.971209:0.895035:0.008179:0.009547:0.004090:0.008179:0.008179:0.008179:0.008179:0.004090:0.008179:0.008179:0.004090:0.008179:0.008179:0.008179:0.008179
S2  Ecotrin 81mg. Each tablet contains Aspirin 81mg. Reg. no.: 29/2.7/0767:@-0.969683:0.829658:-0.458680:0.829658:-0.458680:0.816747:-0.969683:0.816747:0.010185:0.008490:0.004245:0.004245:0.010185:0.007635:0.008490:0.004245:0.005085:0.003390:0.008490:0.004245:0.008490:0.008490:0.012720:0.008490:0.004245:0.004245:0.010185:0.008490:0.007635:0.008490:0.004245:0.004245:0.008490:0.008490:0.003390:0.008490:0.004245:0.004245:0.007635:0.008490:0.008490:0.004245:0.008490:0.003390:0.008490:0.007635:0.003421:0.010185:0.007635:0.008490:0.003390:0.005085:0.003390:0.008490:0.004245:0.008490:0.008490:0.012720:0.008490:0.004245:0.004245:0.011025:0.008490:0.008490:0.004245:0.004245:0.008490:0.008490:0.004245:0.004245:0.004245:0.008490:0.008490:0.004245:0.008490:0.004245:0.008490:0.004245:0.008490:0.008490:0.008490:0.008490
Ecotrin A4 2018 275X210mmAdvert.indd   1:@-1.000585:1.021759:-0.801970:1.021759:-0.801970:1.012422:-1.000585:1.012422:0.006790:0.005090:0.005660:0.002830:0.003390:0.002260:0.005660:0.002830:0.006790:0.005660:0.002830:0.005660:0.005660:0.005660:0.005660:0.002830:0.005660:0.005660:0.005660:0.006790:0.005660:0.005660:0.005660:0.008480:0.008480:0.006790:0.005660:0.005090:0.005660:0.003390:0.002830:0.002830:0.002260:0.005660:0.005660:0.005660:0.002830:0.002830:0.002830:0.005660
2019/07/02   18:11:@-0.099174:1.021759:-0.014271:1.021759:-0.014271:1.012422:-0.099174:1.012422:0.005660:0.005660:0.005660:0.005660:0.002830:0.005660:0.005660:0.002830:0.005660:0.005660:0.002830:0.002830:0.002830:0.005660:0.005660:0.002830:0.005660:0.005660